Meeting
2022 ASCO Genitourinary Cancers Symposium
Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort.
Authors
Adelene Sim Yen Ling
National Cancer Centre, Singapore, Singapore
Adelene Sim Yen Ling , Alexander K. Hakansson , Enya Hui Wen Ong , Amanda S.Y. Lau , Kar Perng Low , Tian Ren Wong , Nicole Tan , Janice Ser Huey Tan , Jeffrey K.L. Tuan , Terence Wee Kiat Tan , Michael L.C. Wang , Kae-Jack Tay , Joe Poh Sheng Yeong , Lui Shiong Lee , Ravindran Kanesvaran , Michael Chien Sheng Tan , Yang Liu , Elai Davicioni , Li Yan Khor , Melvin Lee Kiang Chua
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 273)
DOI
10.1200/JCO.2022.40.6_suppl.273
Abstract #
273
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).
First Author: Ashley Ross
Poster
2016 ASCO Annual Meeting
Development and validation of genomic signature to predict ADT treatment failure.
First Author: Jeffrey Karnes
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.
First Author: Nicholas George Nickols
Poster
2024 ASCO Genitourinary Cancers Symposium
Days spent with healthcare contact by patients with metastatic castrate-resistant prostate cancer in the last year of life.
First Author: Daniel Sentana Lledo